These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8601556)

  • 21. The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients.
    Walczak DD; Apter JT; Halikas JA; Borison RL; Carman JS; Post GL; Patrick R; Cohn JB; Cunningham LA; Rittberg B; Preskorn SH; Kang JS; Wilcox CS
    Ann Clin Psychiatry; 1996 Sep; 8(3):139-51. PubMed ID: 8899132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
    Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
    Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to an open trial of a second SSRI in major depression.
    Joffe RT; Levitt AJ; Sokolov ST; Young LT
    J Clin Psychiatry; 1996 Mar; 57(3):114-5. PubMed ID: 8617695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluvoxamine and mandibular dystonia.
    Chong SA
    Can J Psychiatry; 1995 Sep; 40(7):430-1. PubMed ID: 8548729
    [No Abstract]   [Full Text] [Related]  

  • 25. Suicidal risk during controlled clinical investigations of fluvoxamine.
    Letizia C; Kapik B; Flanders WD
    J Clin Psychiatry; 1996 Sep; 57(9):415-21. PubMed ID: 9746450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluvoxamine for COVID-19?
    Med Lett Drugs Ther; 2021 May; 63(1623):69-70. PubMed ID: 33976099
    [No Abstract]   [Full Text] [Related]  

  • 27. Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors.
    Sheline Y; Bardgett ME; Csernansky JG
    J Clin Psychopharmacol; 1997 Feb; 17(1):11-4. PubMed ID: 9004051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.
    Haffmans PM; Timmerman L; Hoogduin CA
    Int Clin Psychopharmacol; 1996 Sep; 11(3):157-64. PubMed ID: 8923094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.
    Ostroff RB; Nelson JC
    J Clin Psychiatry; 1999 Apr; 60(4):256-9. PubMed ID: 10221288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.
    Dwivedi S; Pavuluri M; Heidenreich J; Wright T
    J Child Adolesc Psychopharmacol; 2002; 12(1):69-70. PubMed ID: 12014598
    [No Abstract]   [Full Text] [Related]  

  • 31. Switching drug class after initial SSRI failure.
    Kelsey JE
    J Clin Psychiatry; 1997 Jul; 58(7):326-7. PubMed ID: 9269258
    [No Abstract]   [Full Text] [Related]  

  • 32. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression.
    Landén M; Björling G; Agren H; Fahlén T
    J Clin Psychiatry; 1998 Dec; 59(12):664-8. PubMed ID: 9921700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluvoxamine: a review of the controlled trials in depression.
    Ware MR
    J Clin Psychiatry; 1997; 58 Suppl 5():15-23. PubMed ID: 9184623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study.
    Ottevanger EA
    Encephale; 1995; 21(4):317-21. PubMed ID: 7588171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder.
    Sato K; Yoshida K; Takahashi H; Ito K; Kamata M; Higuchi H; Shimizu T; Itoh K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K; Otani K
    Neuropsychobiology; 2002; 46(3):136-40. PubMed ID: 12422060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open trial of fluvoxamine therapy for panic disorder complicated by depression.
    Spiegel DA; Saeed SA; Bruce TJ
    J Clin Psychiatry; 1996; 57 Suppl 8():37-40; discussion 40-1. PubMed ID: 8698679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of antidepressant nonresponders: augmentation or switch?
    Nelson JC
    J Clin Psychiatry; 1998; 59 Suppl 15():35-41. PubMed ID: 9786309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of two-phase treatment with imipramine or fluvoxamine, both followed by lithium addition, in inpatients with major depressive disorder.
    Birkenhäger TK; van den Broek WW; Mulder PG; Bruijn JA; Moleman P
    Am J Psychiatry; 2004 Nov; 161(11):2060-5. PubMed ID: 15514407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluvoxamine treatment of major depression associated with multiple sclerosis.
    Benedetti F; Campori E; Colombo C; Smeraldi E
    J Neuropsychiatry Clin Neurosci; 2004; 16(3):364-6. PubMed ID: 15377746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
    J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.